Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-161 in Moderate to Severe Dry Eye Disease
NCT05403827Phase 3Completed
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of K-161 in dry eye disease (DED). Started Jul 2022; status: completed.
02
Drugs
K-161
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05403827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403827.